SAN CARLOS, Calif.--(BUSINESS WIRE)--The Lipoprotein(a) Foundation announced the Centers for Disease Control and Prevention (CDC) has approved two ICD-10 codes for the diagnosis of elevated ...

Dennis R. Leahy, MD, shares his POV on the value of making Lp(a) testing universal, not only to inform patients and their clinicians of the high CV risks, but to make way for potential treatments.

A panel discussion titled “Elevated Lipoprotein(a): Raise Your Game and Lower Your (Risk) Score?” presented at the American Heart Association (AHA) Scientific Sessions 2023, which convened in ...

Roche has received the US Food and Drug Administration’s (FDA) breakthrough device designation for its Tina-quant lipoprotein Lp(a) RxDx assay, a diagnostic tool for cardiovascular disease risk. This ...

A blood test that measures lipoprotein(a) [Lp(a)] has received breakthrough device designation from the US Food and Drug Administration. The Tina-quant Lp(a) RxDx assay, developed by Roche in ...

The main conclusion to draw from this work is that Lp(a) is probably a strong causal factor in not only CAD, but also the development of atherosclerosis in other arterial trees. Although there is no ...

Anjali advises that specific nutrients could aid in the progressive reduction of Lp(a) levels When people think about cholesterol and heart health, they usually focus on total cholesterol and LDL ...

When considering risk factors for heart attacks and strokes, most people think of the usual players: LDL cholesterol (think L for lousy, or “bad”), HDL cholesterol (think H for healthy, or “good”), ...